MCID: PRL017
MIFTS: 49

Prolymphocytic Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Prolymphocytic Leukemia

MalaCards integrated aliases for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia 12 76 15 73
Leukemia, Prolymphocytic 44
Leukemia Prolymphocytic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:1039
MeSH 44 D015463
NCIt 50 C3181
SNOMED-CT 68 10300002
UMLS 73 C0023486

Summaries for Prolymphocytic Leukemia

MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to t-cell prolymphocytic leukemia and b cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Cell cycle. The drugs Ketamine and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are cellular and hematopoietic system

Wikipedia : 76 Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Related Diseases for Prolymphocytic Leukemia

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 t-cell prolymphocytic leukemia 34.1 TCL1A MYC MTCP1 ATM
2 b cell prolymphocytic leukemia 33.0 ZAP70 MYC FCER2 CD5 CD38 CD19
3 lymphoma 30.6 TCL1A MYC CCND1 ATM
4 hairy cell leukemia 30.3 CD5 CCND1 ADA
5 lymphocytic leukemia 30.2 ZAP70 MYC FCER2 CD5 CD38 ATM
6 autoimmune lymphoproliferative syndrome, type v 30.1 TCL1A CD5
7 richter's syndrome 29.8 MYC CD5 CD38 ATM
8 b-cell lymphomas 29.7 TCL1A MYC FCER2 CD5 CCND1
9 anterior scleritis 29.7 CD5 CD19
10 mantle cell lymphoma 29.6 MYC CD5 CD19 CCND1 ATM
11 leukemia, chronic lymphocytic 29.2 ZAP70 TCL1A FCER2 CD5 CD38 CD19
12 splenic manifestation of prolymphocytic leukemia 12.2
13 leukemia 11.1
14 leukemia, chronic lymphocytic 2 10.6
15 leukemia, b-cell, chronic 10.6
16 primary effusion lymphoma 10.2 TCL1A MYC
17 ataxia-telangiectasia 10.1
18 hematopoietic stem cell transplantation 10.1
19 synchronous bilateral breast carcinoma 10.1 CCND1 ATM
20 chromosome 13q14 deletion syndrome 10.1 ZAP70 CD38
21 alk-negative anaplastic large cell lymphoma 10.1 MYC ADA
22 adult lymphoma 10.1 MYC CD5
23 hemimegalencephaly 10.1 MYC CCND1
24 plasmablastic lymphoma 10.1 MYC CD38
25 cd45 deficiency 10.1 ZAP70 CD5
26 kaposi sarcoma 10.1
27 graft-versus-host disease 10.1
28 diffuse large b-cell lymphoma 10.1
29 sarcoma 10.1
30 t-cell leukemia 10.1
31 meningitis 10.1
32 bladder lymphoma 10.0 CD5 CD19
33 colon lymphoma 10.0 CD5 CD19
34 invasive malignant thymoma 9.9 CD38 CD19
35 non-secretory myeloma 9.9 CD38 CD19
36 solitary osseous plasmacytoma 9.9 CD38 CD19
37 gamma heavy chain disease 9.9 CD38 CD19
38 b-cell growth factor 9.9
39 prostate cancer 9.9
40 anemia, autoimmune hemolytic 9.9
41 nijmegen breakage syndrome 9.9
42 kala-azar 1 9.9
43 gastric cancer 9.9
44 infantile liver failure syndrome 1 9.9
45 acute leukemia 9.9
46 acute liver failure 9.9
47 adult t-cell leukemia 9.9
48 hemolytic anemia 9.9
49 peripheral t-cell lymphoma 9.9
50 thrombocytopenia 9.9

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:



Diseases related to Prolymphocytic Leukemia

Symptoms & Phenotypes for Prolymphocytic Leukemia

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 ABCB4 ADA ATM CCND1 CD19 CD38
2 hematopoietic system MP:0005397 10.02 ABCB4 ADA ATM CCND1 CD19 CD38
3 immune system MP:0005387 9.96 ABCB4 ADA ATM CCND1 CD19 CD38
4 endocrine/exocrine gland MP:0005379 9.91 ABCB4 ADA ATM CCND1 CD38 MYC
5 digestive/alimentary MP:0005381 9.88 ABCB4 ADA CCND1 CD19 FCER2 MYC
6 integument MP:0010771 9.63 ATM CCND1 CD19 CD5 MYC ZAP70
7 neoplasm MP:0002006 9.35 ABCB4 ATM CCND1 CD19 MYC
8 normal MP:0002873 9.1 ADA CCND1 CD19 CD5 MYC ZAP70

Drugs & Therapeutics for Prolymphocytic Leukemia

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
5
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
6
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
7
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
9
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
10
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
11
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
12
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Iron Approved Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
15
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
18
Dalteparin Approved Phase 3 9005-49-6
19
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
20
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
22
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
23
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
24
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
25
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
26
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
27
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
28
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
29 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
30 Anesthetics, Dissociative Phase 3
31 Anesthetics, General Phase 3
32 Excitatory Amino Acid Antagonists Phase 3
33 Excitatory Amino Acids Phase 3
34 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
35 Analgesics Phase 3,Phase 2,Not Applicable
36 Anesthetics, Intravenous Phase 3
37 Neurotransmitter Agents Phase 3,Not Applicable
38 Anesthetics Phase 3
39 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Renal Agents Phase 3,Phase 1,Phase 2
42 Cephalosporins Phase 3,Phase 1
43 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Infective Agents, Urinary Phase 3,Phase 1,Phase 2
46 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Not Applicable
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
4 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
7 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
8 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
11 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
12 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
13 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
14 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
15 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
16 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
17 ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Unknown status NCT02029443 Phase 1, Phase 2 acalabrutinib
18 Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy Unknown status NCT01735604 Phase 1, Phase 2
19 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
20 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
21 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
22 Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
23 Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) Completed NCT00464633 Phase 2 alvocidib
24 Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL Completed NCT00452374 Phase 1, Phase 2 Cytarabine;Fludarabine;Oxaliplatin;Rituximab
25 Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias Completed NCT00472849 Phase 1, Phase 2 Oxaliplatin;Fludarabine;Cytarabine;Rituximab;Pegfilgrastim
26 Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma Completed NCT00006252 Phase 2 fludarabine phosphate;Cyclophosphamide;G-CSF
27 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
28 Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) Completed NCT00005626 Phase 2 Irinotecan
29 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
30 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
31 Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia Completed NCT02530515 Phase 2
32 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
33 Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases Completed NCT00309842 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
34 Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
35 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Completed NCT00364286 Phase 2 Dasatinib (BMS-354825)
36 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Completed NCT01244906 Phase 2
37 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
38 Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Completed NCT00782379 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
39 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
40 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
41 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
42 Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma Completed NCT00278161 Phase 2 Cyclophosphamide
43 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
44 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
45 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
46 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
47 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
48 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
49 Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed NCT00026351 Phase 2 pentostatin
50 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Genetic Tests for Prolymphocytic Leukemia

Anatomical Context for Prolymphocytic Leukemia

MalaCards organs/tissues related to Prolymphocytic Leukemia:

41
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Nk Cells, Liver

Publications for Prolymphocytic Leukemia

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 351)
# Title Authors Year
1
T-cell prolymphocytic leukemia negative for surface CD3 and CD45. ( 29976781 )
2018
2
Exploring the molecular pathogenesis associated with T-cell prolymphocytic leukemia based on a comprehensive bioinformatics analysis. ( 29928415 )
2018
3
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. ( 29407180 )
2018
4
Papuloerythroderma-like cutaneous involvement of a CD62L- subclone of T-cell prolymphocytic leukemia. ( 30450688 )
2018
5
Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric Vβ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases. ( 30414304 )
2018
6
T Cell Prolymphocytic Leukemia (T-PLL): Cutaneous Involvement in an Uncommon Leukemia. ( 30127581 )
2018
7
T-Cell Prolymphocytic Leukemia: An Experience from a Tertiary Cancer Centre in South India. ( 30233775 )
2018
8
Concomitant T-cell prolymphocytic leukemia and visceral leishmaniasis: A case report. ( 30235714 )
2018
9
Auer Rod-Like Inclusions in B-cell prolymphocytic leukemia. ( 30238921 )
2018
10
A Novel Treatment With Obinutuzumab-Chlorambucil in a Patient With B-Cell Prolymphocytic Leukemia: A Case Report and Review of the Literature. ( 30038912 )
2018
11
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia. ( 29352181 )
2018
12
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. ( 29483097 )
2018
13
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 28377595 )
2017
14
Risk of second cancers in survivors of prolymphocytic leukemia: a SEER data analysis. ( 27924652 )
2017
15
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. ( 28194886 )
2017
16
The distinctive cytological features of T-cell prolymphocytic leukemia. ( 28120343 )
2017
17
Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion. ( 28819574 )
2017
18
A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia. ( 28435655 )
2017
19
T-cell Prolymphocytic Leukemia. ( 28340878 )
2017
20
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. ( 28972014 )
2017
21
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
22
Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma. ( 29199492 )
2017
23
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
24
Modified Hyper-CVAD Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation Successfully Treated Synchronous T-Cell Prolymphocytic Leukemia and Gastric Cancer in a 68-Year-Old Female. ( 28824253 )
2017
25
T-cell prolymphocytic leukemia and tuberculosis: a puzzling association. ( 28878921 )
2017
26
Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations. ( 28695755 )
2017
27
TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. ( 28232160 )
2017
28
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). ( 28379307 )
2017
29
Broken heart by T-prolymphocytic leukemia. ( 28775161 )
2017
30
Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment. ( 28324286 )
2017
31
T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib). ( 29296924 )
2017
32
Advances in the understanding and management of T-cell prolymphocytic leukemia. ( 29262669 )
2017
33
PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP. ( 27168399 )
2016
34
Brentuximab Vedotin Therapy for Cutaneous Lesions in T-Prolymphocytic Leukemia: A Case Report. ( 27757215 )
2016
35
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
36
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
37
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 27941777 )
2016
38
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2016
39
A I^/I' T-cell Receptor Prolymphocytic Leukemia and CD4-/CD8- Double-negative Immunophenotype in a Pediatric Patient. ( 25757027 )
2015
40
T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine. ( 26853400 )
2015
41
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL). ( 25888568 )
2015
42
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
43
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
44
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
45
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AA Single-Center Experience. ( 26422251 )
2015
46
Management of prolymphocytic leukemia. ( 26637744 )
2015
47
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
48
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
49
Auer Rod-Like Inclusions in Prolymphocytic Leukemia. ( 26299084 )
2015
50
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015

Variations for Prolymphocytic Leukemia

Expression for Prolymphocytic Leukemia

Search GEO for disease gene expression data for Prolymphocytic Leukemia.

Pathways for Prolymphocytic Leukemia

GO Terms for Prolymphocytic Leukemia

Cellular components related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 ADA CD19 CD5 FCER2

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.81 ADA CD38 MYC TCL1A
2 positive regulation of cell proliferation GO:0008284 9.8 CCND1 CD38 MYC TCL1A
3 response to hypoxia GO:0001666 9.65 ADA ATM CD38
4 response to estradiol GO:0032355 9.58 CCND1 CD38 MYC
5 liver regeneration GO:0097421 9.52 CCND1 MYC
6 positive regulation of T cell differentiation GO:0045582 9.46 ADA ZAP70
7 positive regulation of calcium-mediated signaling GO:0050850 9.43 ADA ZAP70
8 positive regulation of response to DNA damage stimulus GO:2001022 9.37 ATM MYC
9 positive regulation of mitochondrial membrane potential GO:0010918 9.32 MYC TCL1A
10 positive regulation of alpha-beta T cell differentiation GO:0046638 9.26 ADA ZAP70
11 response to vitamin E GO:0033197 9.16 ADA CCND1
12 response to drug GO:0042493 9.02 ABCB4 ADA CCND1 CD38 MYC
13 re-entry into mitotic cell cycle GO:0000320 8.96 CCND1 MYC

Molecular functions related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activator activity GO:0043539 8.62 MTCP1 TCL1A

Sources for Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....